

Tanya L Applegate

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6538405/publications.pdf>

Version: 2024-02-01

85
papers

3,121
citations

186265

28
h-index

168389

53
g-index

85
all docs

85
docs citations

85
times ranked

3752
citing authors

#	ARTICLE	IF	CITATIONS
1	Diagnostic Accuracy of Assays Using Point-of-Care Testing or Dried Blood Spot Samples for the Determination of Hepatitis C Virus RNA: A Systematic Review. <i>Journal of Infectious Diseases</i> , 2022, 226, 1005-1021.	4.0	24
2	Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals. <i>JHEP Reports</i> , 2022, 4, 100462.	4.9	10
3	Reinfection Following Successful Direct-acting Antiviral Therapy for Hepatitis C Virus Infection Among People Who Inject Drugs. <i>Clinical Infectious Diseases</i> , 2021, 72, 1392-1400.	5.8	26
4	Evaluation of the Aptima HCV Quant Dx Assay for Hepatitis C Virus RNA Detection from Fingerstick Capillary Dried Blood Spot and Venepuncture-Collected Samples. <i>Journal of Infectious Diseases</i> , 2021, 223, 818-826.	4.0	7
5	Evaluation of Hepatitis C Virus Core Antigen Assay in a Resource-Limited Setting in Pakistan. <i>Diagnostics</i> , 2021, 11, 1354.	2.6	5
6	Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection. <i>Journal of Hepatology</i> , 2021, 75, 829-839.	3.7	27
7	Moving Towards Hepatitis C Microelimination Among People Living With Human Immunodeficiency Virus in Australia: The CEASE Study. <i>Clinical Infectious Diseases</i> , 2020, 71, 1502-1510.	5.8	46
8	Hepatitis C virus testing, liver disease assessment and treatment uptake among people who inject drugs pre- and post-universal access to direct-acting antiviral treatment in Australia: The LiveRLife study. <i>Journal of Viral Hepatitis</i> , 2020, 27, 281-293.	2.0	39
9	Modeling based response guided therapy in subjects with recent hepatitis C infection. <i>Antiviral Research</i> , 2020, 180, 104862.	4.1	6
10	Novel Hepatitis C Virus (HCV) Diagnosis and Treatment Delivery Systems: Facilitating HCV Elimination by Thinking Outside the Clinic. <i>Journal of Infectious Diseases</i> , 2020, 222, S758-S772.	4.0	15
11	Elbasvir and grazoprevir for hepatitis C virus genotype 1 infection in people with recent injecting drug use (DARLOAC): An open-label, single-arm, phase 4, multicentre trial. <i>Health Science Reports</i> , 2020, 3, e151.	1.5	4
12	Time to Detection of Hepatitis C Virus Infection With the Xpert HCV Viral Load Fingerstick Point-of-Care Assay: Facilitating a More Rapid Time to Diagnosis. <i>Journal of Infectious Diseases</i> , 2020, 221, 2043-2049.	4.0	16
13	Evaluation of a hepatitis C virus core antigen assay from venepuncture and dried blood spot collected samples: A cohort study. <i>Journal of Viral Hepatitis</i> , 2019, 26, 1423-1430.	2.0	12
14	Performance evaluation of the Hologic Aptima HCV Quant Dx assay for detection of HCV RNA from dried blood spots. <i>Journal of Clinical Virology</i> , 2019, 112, 40-44.	3.1	16
15	Hepatitis C virus testing, liver disease assessment and direct-acting antiviral treatment uptake and outcomes in a service for people who are homeless in Sydney, Australia: The LiveRLife homelessness study. <i>Journal of Viral Hepatitis</i> , 2019, 26, 969-979.	2.0	25
16	Genomic characterization of hepatitis C virus transmitted founder variants with deep sequencing. <i>Infection, Genetics and Evolution</i> , 2019, 71, 36-41.	2.3	14
17	A latent class approach to identify multi-risk profiles associated with phylogenetic clustering of recent hepatitis C virus infection in Australia and New Zealand from 2004 to 2015. <i>Journal of the International AIDS Society</i> , 2019, 22, e25222.	3.0	6
18	Genomic variability of within-host hepatitis C variants in acute infection. <i>Journal of Viral Hepatitis</i> , 2019, 26, 476-484.	2.0	6

#	ARTICLE	IF	CITATIONS
19	A systematic, deep sequencing-based methodology for identification of mixed-genotype hepatitis C virus infections. <i>Infection, Genetics and Evolution</i> , 2019, 69, 76-84.	2.3	6
20	Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 135-184.	8.1	370
21	Shortened therapy of eight weeks with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with recent <sc>HCV</sc> genotype 1 infection. <i>Journal of Viral Hepatitis</i> , 2018, 25, 1180-1188.	2.0	25
22	Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 153-161.	8.1	231
23	Evaluation of the Xpert HCV Viral Load Finger-Stick Point-of-Care Assay. <i>Journal of Infectious Diseases</i> , 2018, 217, 1889-1896.	4.0	88
24	HCV avidity as a tool for detection of recent HCV infection: Sensitivity depends on HCV genotype. <i>Journal of Medical Virology</i> , 2018, 90, 120-130.	5.0	6
25	Adherence to sofosbuvir and velpatasvir among people with chronic HCV infection and recent injection drug use: The SIMPLIFY study. <i>International Journal of Drug Policy</i> , 2018, 62, 14-23.	3.3	58
26	Acceptability and preferences of point-of-care finger-stick whole-blood and venepuncture hepatitis C virus testing among people who inject drugs in Australia. <i>International Journal of Drug Policy</i> , 2018, 61, 23-30.	3.3	57
27	Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy. <i>International Journal of Drug Policy</i> , 2018, 62, 94-103.	3.3	22
28	Hepatitis C Virus Diagnosis and the Holy Grail. <i>Infectious Disease Clinics of North America</i> , 2018, 32, 425-445.	5.1	52
29	Evaluation of a Hepatitis C Virus Core Antigen Assay in Plasma and Dried Blood Spot Samples. <i>Journal of Molecular Diagnostics</i> , 2018, 20, 621-627.	2.8	17
30	Limited naturally occurring escape in broadly neutralizing antibody epitopes in hepatitis C glycoprotein E2 and constrained sequence usage in acute infection. <i>Infection, Genetics and Evolution</i> , 2017, 49, 88-96.	2.3	8
31	Dynamic evolution of hepatitis C virus resistance-associated substitutions in the absence of antiviral treatment. <i>Scientific Reports</i> , 2017, 7, 41719.	3.3	12
32	IFN- γ 3, not IFN- γ 4, likely mediates IFNL3-IFNL4 haplotype-dependent hepatic inflammation and fibrosis. <i>Nature Genetics</i> , 2017, 49, 795-800.	21.4	86
33	Evaluation of the Xpert HCV Viral Load point-of-care assay from venepuncture-collected and finger-stick capillary whole-blood samples: a cohort study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 514-520.	8.1	123
34	Hepatitis C virus core antigen: A simplified treatment monitoring tool, including for post-treatment relapse. <i>Journal of Clinical Virology</i> , 2017, 92, 32-38.	3.1	32
35	<sc>HCV</sc> reinfection incidence among individuals treated for recent infection. <i>Journal of Viral Hepatitis</i> , 2017, 24, 359-370.	2.0	68
36	Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study. <i>International Journal of Drug Policy</i> , 2017, 47, 177-186.	3.3	13

#	ARTICLE	IF	CITATIONS
37	Hepatitis C point-of-care diagnostics: in search of a single visit diagnosis. <i>Expert Review of Molecular Diagnostics</i> , 2017, 17, 1109-1115.	3.1	116
38	Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study. <i>BMC Infectious Diseases</i> , 2017, 17, 420.	2.9	6
39	Phylogenetic analysis of full-length, early infection, hepatitis C virus genomes among people with intravenous drug use: the InC ³ Study. <i>Journal of Viral Hepatitis</i> , 2017, 24, 43-52.	2.0	14
40	Analysis of resistance-associated substitutions in acute hepatitis C virus infection by deep sequencing across six genotypes and three continents. <i>Journal of Viral Hepatitis</i> , 2017, 24, 37-42.	2.0	11
41	A molecular transmission network of recent hepatitis C infection in people with and without HIV: Implications for targeted treatment strategies. <i>Journal of Viral Hepatitis</i> , 2017, 24, 404-411.	2.0	23
42	Sequencing of hepatitis C virus for detection of resistance to direct-acting antiviral therapy: A systematic review. <i>Hepatology Communications</i> , 2017, 1, 379-390.	4.3	26
43	Maximum levels of hepatitis C virus lipoviral particles are associated with early and persistent infection. <i>Liver International</i> , 2016, 36, 1774-1782.	3.9	8
44	Short Duration Response-Guided Treatment is Effective for Most Individuals with Recent Hepatitis C Infection: The ATAHC II and DARE-C I Studies. <i>Antiviral Therapy</i> , 2016, 21, 465-465.	1.0	5
45	Transmission of hepatitis C virus infection among younger and older people who inject drugs in Vancouver, Canada. <i>Journal of Hepatology</i> , 2016, 64, 1247-1255.	3.7	18
46	Historical Trends in the Hepatitis C Virus Epidemics in North America and Australia. <i>Journal of Infectious Diseases</i> , 2016, 214, 1383-1389.	4.0	16
47	Sofosbuvir and ribavirin for 6 weeks is not effective among people with recent hepatitis C virus infection: The DARE II study. <i>Hepatology</i> , 2016, 64, 1911-1921.	7.3	50
48	Short Duration Response-Guided Treatment is Effective for Most Individuals with Recent Hepatitis C Infection: The ATAHC II and DARE-C I Studies. <i>Antiviral Therapy</i> , 2016, 21, 425-434.	1.0	6
49	Alanine aminotransferase, HCV RNA levels and pro-inflammatory and pro-fibrogenic cytokines/chemokines during acute hepatitis C virus infection. <i>Virology Journal</i> , 2016, 13, 32.	3.4	10
50	Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes. <i>Hepatology</i> , 2016, 64, 34-46.	7.3	83
51	HIV infection is associated with higher levels of monocyte chemoattractant protein-1 and eotaxin among people with recent hepatitis C virus infection. <i>BMC Infectious Diseases</i> , 2016, 16, 241.	2.9	5
52	HIV infection and hepatitis C virus genotype 1a are associated with phylogenetic clustering among people with recently acquired hepatitis C virus infection. <i>Infection, Genetics and Evolution</i> , 2016, 37, 252-258.	2.3	13
53	Venue-Based Networks May Underpin HCV Transmissions amongst HIV-Infected Gay and Bisexual Men. <i>PLoS ONE</i> , 2016, 11, e0162002.	2.5	8
54	Naturally Occurring Dominant Drug Resistance Mutations Occur Infrequently in the Setting of Recently Acquired Hepatitis C. <i>Antiviral Therapy</i> , 2015, 20, 199-208.	1.0	21

#	ARTICLE	IF	CITATIONS
55	Patterns of Hepatitis C Virus RNA Levels during Acute Infection: The InC3 Study. PLoS ONE, 2015, 10, e0122232.	2.5	41
56	Methamphetamine injecting is associated with phylogenetic clustering of hepatitis C virus infection among street-involved youth in Vancouver, Canada. Drug and Alcohol Dependence, 2015, 152, 272-276.	3.2	29
57	Interferon λ 3 and 4 Genotyping Using High-Resolution Melt Curve Analysis Suitable for Multiple Clinical Sample Types. Journal of Molecular Diagnostics, 2015, 17, 583-589.	2.8	3
58	A molecular phylogenetics-based approach for identifying recent hepatitis C virus transmission events. Infection, Genetics and Evolution, 2015, 33, 101-109.	2.3	23
59	A longitudinal study of hepatitis C virus testing and infection status notification on behaviour change in people who inject drugs. Journal of Epidemiology and Community Health, 2015, 69, 745-752.	3.7	21
60	Factors associated with hepatitis C virus RNA levels in early chronic infection: the InC3 study. Journal of Viral Hepatitis, 2015, 22, 708-717.	2.0	13
61	Mixed HCV infection and reinfection in people who inject drugs—impact on therapy. Nature Reviews Gastroenterology and Hepatology, 2015, 12, 218-230.	17.8	79
62	A Comparison of Seminal Hepatitis C Virus (HCV) RNA Levels During Recent and Chronic HCV Infection in HIV-Infected and HIV-Uninfected Individuals. Journal of Infectious Diseases, 2015, 211, 736-743.	4.0	30
63	The Influence of Hepatitis C Virus Genetic Region on Phylogenetic Clustering Analysis. PLoS ONE, 2015, 10, e0131437.	2.5	48
64	Phylogenetic clustering of hepatitis C virus among people who inject drugs in Vancouver, Canada. Hepatology, 2014, 60, 1571-1580.	7.3	59
65	A Quantitative Comparison of Anti-HIV Gene Therapy Delivered to Hematopoietic Stem Cells versus CD4+ T Cells. PLoS Computational Biology, 2014, 10, e1003681.	3.2	15
66	Interferon lambda 3 genotype predicts hepatitis C virus RNA levels in early acute infection among people who inject drugs: The InC3 Study. Journal of Clinical Virology, 2014, 61, 430-434.	3.1	8
67	Dynamics of HCV RNA levels during acute hepatitis C virus infection. Journal of Medical Virology, 2014, 86, 1722-1729.	5.0	26
68	Plasma interferon-gamma-inducible protein-10 (IP-10) levels during acute hepatitis C virus infection. Hepatology, 2013, 57, 2124-2134.	7.3	61
69	Sequencing of the Hepatitis C Virus: A Systematic Review. PLoS ONE, 2013, 8, e67073.	2.5	25
70	Plasma Interferon-Gamma-Inducible Protein-10 Levels Are Associated with Early, but Not Sustained Virological Response during Treatment of Acute or Early Chronic HCV Infection. PLoS ONE, 2013, 8, e80003.	2.5	9
71	Virological responses during treatment for recent hepatitis C virus. Aids, 2012, 26, 1653-1661.	2.2	27
72	Multiple shRNA combinations for near-complete coverage of all HIV-1 strains. AIDS Research and Therapy, 2011, 8, 1.	1.7	33

#	ARTICLE	IF	CITATIONS
73	Potential role for Interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection. <i>Hepatology</i> , 2010, 52, 1216-1224.	7.3	156
74	In silico modeling indicates the development of HIV-1 resistance to multiple shRNA gene therapy differs to standard antiretroviral therapy. <i>Retrovirology</i> , 2010, 7, 83.	2.0	16
75	Towards a Clinically Relevant Lentiviral Transduction Protocol for Primary Human CD34+ Hematopoietic Stem/Progenitor Cells. <i>PLoS ONE</i> , 2009, 4, e6461.	2.5	44
76	96 shRNAs designed for maximal coverage of HIV-1 variants. <i>Retrovirology</i> , 2009, 6, 55.	2.0	38
77	Cassette deletion in multiple shRNA lentiviral vectors for HIV-1 and its impact on treatment success. <i>Virology Journal</i> , 2009, 6, 184.	3.4	19
78	An Infinitely Expandable Cloning Strategy plus Repeat-Proof PCR for Working with Multiple shRNA. <i>PLoS ONE</i> , 2008, 3, e3827.	2.5	12
79	Non-Oxidative Metabolism of Ethanol by Rat Pancreatic Acini. <i>Pancreatology</i> , 2004, 4, 82-89.	1.1	45
80	Diagnosis and Molecular Monitoring of Acute Promyelocytic Leukemia Using DzyNA Reverse Transcription-PCR to Quantify PML/RAR α Fusion Transcripts. <i>Clinical Chemistry</i> , 2002, 48, 1338-1343.	3.2	9
81	Factors That Influence Deoxyribozyme Cleavage during Polymerase Chain Reaction. <i>Analytical Biochemistry</i> , 2000, 286, 300-303.	2.4	4
82	DzyNA-PCR: Use of DNAzymes to Detect and Quantify Nucleic Acid Sequences in a Real-Time Fluorescent Format. <i>Clinical Chemistry</i> , 2000, 46, 625-630.	3.2	83
83	Metabolism of ethanol by rat pancreatic acinar cells. <i>Translational Research</i> , 1998, 132, 294-302.	2.3	87
84	The effect of ethanol on pancreatic enzymes—a dietary artefact?. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 1998, 1379, 314-324.	2.4	19
85	Rapid Ca ²⁺ influx induced by the action of dibutylhydroquinone and glucagon in the perfused rat liver. <i>Biochemical Journal</i> , 1997, 323, 463-467.	3.7	22